Efalizumab discontinuation: A practical strategy

Journal of Dermatological Treatment

Volumn 20, Issue 3, 2009, Pages 132-136

  Pugashetti, Rupa ^a   Koo, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Discontinuation; Efalizumab; Progressive multifocal leukoencephalopathy; Psoriasis; Rebound

Indexed keywords

ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; STEROID; VITAMIN D;

ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; PHENOMENOLOGY; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUSTULAR PSORIASIS; PUVA; REBOUND; RISK FACTOR; TREATMENT DURATION; ULTRAVIOLET B RADIATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL; CANADA; DRUG AND NARCOTIC CONTROL; DRUG TOXICITY; EUROPE; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; PSORIASIS; RISK ASSESSMENT; UNITED STATES; WITHHOLDING TREATMENT;

EID: 67650663801     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630902984596     Document Type: Article

References (15)

1. Leonardi C, Menter a, hamilton t, Caro I, Xing B, gottlieb aB. efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol. 2008;158:1107-16.
2. genentech announces Voluntary Withdrawal of Raptiva from the U.S. Market [press release on the Internet]. genentech, Inc. South San Francisco, Ca. april 8, 2009. available from: http://www.gene.com/gene/news/press-releases/display. do?method=detail&id=12047.
3. Carey W, glazer S, gottlieb aB, Lebwohl M, Leonardi C, Menter a, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J am acad Dermatol. 2006;54:S171-81.
4. gordon KB, Feldman SR, Koo JY, Menter a, Rolstad t, Krueger g. Defnitions of measures of effect duration for psoriasis treatments. arch Dermatol. 2005;141:82-4.
5. Scheinfeld N. efalizumab: a review of events reported during clinical trials and side effects. expert Opin Drug Saf. 2006;5:197-209.
6. Cather JC, Cather JC, Menter a. Modulating t cell responses for the treatment of psoriasis: a focus on efalizumab. expert Opin Biol ther. 2003;3:361-70.
7. puig L, Roé e, garcía-navarro X, Corella F, alomar a. efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice. Clin exp Dermatol. 2008; Dec 2. epub ahead of print
8. tsai tF, Liu Mt, Liao Yh, Licu D. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in taiwan: results of an open-label, single-arm pilot study. J eur acad Dermatol Venereol. 2008;22:345-52.
9. Maskatia ZK, Koo J. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine. J Drugs Dermatol. 2007;6:941-4.
10. golda N, Benham SM, Koo J. Rebound of psoriasis during treatment with efalizumab. J Drugs Dermatol. 2006;5:63-5.
11. thielen aM, Barde C, Saurat Jh. Infiximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva). Br J Dermatol. 2006;155:846-7.
12. Menter a, hamilton tK, toth Dp, Leung hM, Wetherill g, hennessey B, et al. transitioning patients from efalizumab to alternative psoriasis therapies: Findings from an open-label, multicenter, phase IIIb study. Int J Dermatol. 2007;46:637-48.
13. Carey W, Rundle aC, Kwon p, Leonardi CL. taper regimens in the management of patients discontinuing efalizumab therapy. poster 29 presented at: 10th annual International psoriasis Symposium; June 10-13, 2004; toronto, Ontario, Canada.
14. papp Ka, toth D, Rosoph L. approaches to discontinuing efalizumab: Results of an open-label study comparing different transitioning therapies. poster pDt9 presented at: 3rd european academy of Dermatology and Venereology Spring Symposium; May 19-22, 2005; Sofa, Bulgaria.
15. Menter a, tyring SK, gordon K, Kimball aB, Leonardi CL, Langley Rg, et al. adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J am acad Dermatol. 2008;58:106-15.